Citigroup Maintains Neutral on Hims & Hers Health, Lowers Price Target to $33
Citigroup analyst Daniel Grosslight maintains Hims & Hers Health (NYSE: HIMS ) with a Neutral and lowers the price target from $35 to $33.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.